The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNIT	UNITED STATES SECURITIES AND EXCHANGE COMMISSION			
		gton, D.C. 20549 F ORM D		OMB Number: 3235-0076
	I			Estimated average burden hours per response: 4.00
	Notice of Exemp	ot Offering of Secu	rities	
1. Issuer's Identity				
CIK (Filer ID Number)	Previous Names	X None	Entity Type	
0001541157			X Corporation	
Name of Issuer			Limited Partner	ship
Morria Biopharmaceuticals PLC			Limited Liability	
Jurisdiction of Incorporation/Org	ganization			
UNITED KINGDOM	-		General Partner	•
Year of Incorporation/Organizat	ion		Business Trust	
X Over Five Years Ago			Other (Specify)	
Within Last Five Years (Spe	ecifv Year)			
Yet to Be Formed	,			
2. Principal Place of Business	and Contact Information			
Name of Issuer				
Morria Biopharmaceuticals PLC				
Street Address 1		Street Address 2		
53 DAVIES STREET				
City	State/Province/Country	ZIP/PostalCode	Phone Number of	Issuer
LONDON	UNITED KINGDOM	W1K 5JH	212-533-5765	
3. Related Persons				
Last Name	First Name		Middle Name	
Cohen	Yuval			
Street Address 1	Street Address 2			
53 Davies Street	Mayfair			
City	State/Province/C	ountry	ZIP/PostalCode	
London	UNITED KINGDO	M	W1K 5JH	
Relationship: X Executive Offi	cer X Director Promoter			
Clarification of Response (if Nec	cessary):			
Last Name	First Name		Middle Name	
Elefant	Dov			
Street Address 1	Street Address 2			
53 Davies Street	Mayfair			
City	State/Province/C	ountry	ZIP/PostalCode	
London	UNITED KINGDO	М	W1K 5JH	
Relationship: X Executive Offi	cer Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name		Middle Name	
Yedgar	Saul			
Street Address 1	Street Address 2			
Department of Biochemistry	Hebrew University	- Hadassah Medical Sch		

City Jerusalem	State/Province/Country ISRAEL	ZIP/PostalCode 91120
Relationship: X Executive Officer X Direct	ctor Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Bondi	Joe	
Street Address 1	Street Address 2	
110 Glenwood Avenue		
City	State/Province/Country	ZIP/PostalCode
Collegeville	PENNSYLVANIA	19426
Relationship: X Executive Officer Direct	ctor Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Cohen	Mark	
Street Address 1	Street Address 2	
Chairman, Pearl Cohen Zedek Latzer, LLP	1500 Broadway, 12th Floor	
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10036
Relationship: Executive Officer X Direct	ctor Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Lau	Johnson	
Street Address 1	Street Address 2	
701 Ellicott Street		
City	State/Province/Country	ZIP/PostalCode
Buffalo	NEW YORK	14203
Relationship: Executive Officer X Direct	ctor Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Raday	Gilead	
Street Address 1 255 Kefar-Uria	Street Address 2	
City	State/Province/Country	ZIP/PostalCode
Kefar-Uria	ISRAEL	99735
Relationship: Executive Officer X Direct		
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Sidransky	David	
Street Address 1	Street Address 2	
17 Pinsker Street		
City	State/Province/Country	ZIP/PostalCode
Rehovot	ISRAEL	76308
Relationship: Executive Officer X Direct	ctor Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Eiran	Amos	
Street Address 1	Street Address 2	

2 Avner St. City State/Province/Country Herzeliya ISRAEL Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary):	ZIP/PostalCode 46662
4. Industry Group	
Agriculture Health Care Banking & Financial Services Isourance Commercial Banking Health Insurance Insurance Hospitals & Physicians Investing Pharmaceuticals Investment Banking Other Health Care Investment Banking Other Health Care Investment Banking Other Health Care Is the issuer registered as an investment company under the Investment Company Act of 1940? Manufacturing Yes No Other Banking & Financial Services REITS & Finance Business Services Residential Energy Other Real Estate Coal Mining Other Real Estate Energy Conservation Environmental Services Oil & Gas Other Energy	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel Other Travel

5. Issuer Size

	00		
Revenue Range	OR	Aggregate Net Asset Value Range	
X No Revenues		No Aggregate Net Asset Value	
\$1 - \$1,000,000		\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000	
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000	
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000	
Over \$100,000,000		Over \$100,000,000	
Decline to Disclose		Decline to Disclose	
Not Applicable		Not Applicable	
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)			
		יט נשכובטו מוו נוומו מאאואא	
Rule 504(b)(1) (not (i), (ii) or	r (iii))	Rule 505	

Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)

Rule 504 (b)(1)(iii)

Rule 505

X Rule 506

Securities Act Section 4(6)

Investment Company Act Section 3(c)

Section	n 3(c)(1) Section 3(c)(9) n 3(c)(2) Section 3(c)(10) n 3(c)(3) Section 3(c)(11) n 3(c)(4) Section 3(c)(12)	
	n 3(c)(5) Section 3(c)(13)	
	n 3(c)(6) Section 3(c)(14)	
	n 3(c)(7)	
7. Type of Filing		
X New Notice Date of First Sale X First Sale Yet to Occur Amendment		
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
 X Equity X Debt X Option, Warrant or Other Right to Acquire Another Security X Security to be Acquired Upon Exercise of Option, Warrant or Right to Acquire Security 	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combin merger, acquisition or exchange offer?	nation transaction, such as a	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USE		
12. Sales Compensation		
Recipient	Recipient CRD Number X None	
N/A	None	
(Associated) Broker or Dealer X None	ociated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None	
None Street Address 1	t Address 1 Street Address 2	
N/A	Stiel Address 2	
City	State/Province/Country	ZIP/Postal Code
N/A	UNITED STATES	00000
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
NEW YORK		
13. Offering and Sales Amounts		
Total Offering Amount \$1,100,000 USD or Indefinite		
Total Amount Sold \$0 USD		

Total Remaining to be Sold \$1,100,000 USD or		Indefinite
---	--	------------

Clarification of Response (if Necessary):

14. Investors	
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.	
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:	2

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate

Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$111,000 USD X Estimate

Clarification of Response (if Necessary):

Amounts are for payment of salaries for executives

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Morria Biopharmaceuticals PLC	/s/ Yuval Cohen	Yuval Cohen	President	2012-04-13

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the

ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.